Healthcare & Life Sciences

Compstatin Analogues Patent for Complement Inhibitors

USPTO granted patent US12600749B2 to ZP SPV 3 K/S on April 14, 2026, covering compstatin analogues with improved complement-inhibiting activity. The patent includes 19 claims for peptide variants with modifications at positions 3 and 9, as well as terminal sequences, providing improved binding affinity and solubility. Inventors include Anne Pernille Tofteng Shelton, Jacob Ulrik Fog, and Jens Kvist Madsen.

RSV Vaccine Methods for Inactivating and Stabilizing Pre-F Protein

USPTO granted patent US12600750B2 to Xiamen University covering methods for inactivating respiratory syncytial virus (RSV) and stabilizing pre-F protein. The patent also covers inactivated RSV virus obtained by the method, vaccines comprising the inactivated virus, and uses of the vaccine for preventing or treating RSV infection. The patent names six inventors including Zizheng Zheng, Wei Zhang, and Ningshao Xia, with 19 claims total.

Cobra 1/NELF-B as Booster for CD8+ T Cell-Based Therapy - US12600755B2

The USPTO granted Patent US12600755B2 to The George Washington University on April 14, 2026. The patent covers methods of generating T cells with integrated transgenes encoding negative elongation factor (NELF) complex subunits, specifically Cobra 1/NELF-B, for use in treating cancer and infectious disease. The patent contains 19 claims.

Native Chemical Ligation Flow Synthesis - University of Sydney

The USPTO granted Patent US12600746B2 to the University of Sydney covering synthetic methods using native chemical ligation in flow for synthesizing polypeptides. The patent, invented by Richard J. Payne and Tim Chisholm, includes 27 claims and covers selective desulfurization or deselenization of amide-containing compounds with thiol, disulfide, selenol, or diselenide functional groups. The patent application was filed on May 22, 2019, under application number 17057069.

Affinity Chromatography of Immunoglobulins Using Pre-capture Flocculation

USPTO granted patent US12600748B2 to RICHTER GEDEON NYRT on April 14, 2026. The patent covers methods for purifying immunoglobulins from cell culture harvest using pre-capture cleaning steps including flocculation and filtration before affinity chromatography. The invention improves eluted immunoglobulin quality, reduces precipitation during chromatography, and extends the lifetime of affinity resin used in large-scale immunoglobulin production.

Bioactive Polypeptides for Plant Protection, Growth and Productivity

USPTO granted Patent US12599649B2 to Spogen Biotech Inc. covering bioactive priming polypeptides for agricultural applications. The patent protects formulations containing 7 claims that enhance plant growth, yield, health, longevity, productivity, and vigor, while reducing abiotic stress and providing protection from disease, insects, and nematodes. The patent was filed on July 20, 2018.

Modified S2 Subunit Coronavirus Spike Protein Patent US12600751B2

The USPTO granted patent US12600751B2 to inventors Annika Kraemer-Kuehl and Thomas Min Stephan for a modified S2 subunit of coronavirus spike protein featuring a mutation at amino acid position 865. The patent covers a recombinant avian coronavirus spike protein or fragment thereof, along with an immunogenic composition containing the modified spike protein. The patent includes 22 claims with filing date May 6, 2020.

Pharmaceutical Compositions with NSAID and Fatty Acid Oxidase Inhibitor for Treating Infections, Inflammation, Aging

The USPTO granted patent US12599614B2 to MD VAULT LLC for pharmaceutical compositions combining non-steroidal anti-inflammatory drugs (NSAIDs) with fatty acid oxidation inhibitors for treating microbial infectious diseases, associated inflammatory disorders, and aging-related conditions. The patent, filed December 13, 2021, contains 9 claims and covers compositions including agents such as diclofenac (A61K 31/616), mefenamic acid (A61K 31/495), and phenylbutazone (A61K 31/192).

Timolol Compositions for Glaucoma Treatment, Novaliq

USPTO granted patent US12599607B2 to Novaliq GmbH on April 14, 2026, covering pharmaceutical compositions comprising timolol (a β1-receptor blocker) combined with a semifluorinated alkane liquid vehicle for topical ophthalmic administration. The patented compositions are intended for treatment of glaucoma, elevated intraocular pressure, ocular hypertension, and associated symptoms. The patent contains 21 allowed claims.

Methods for Treating Cardiac Valve Disease Using Pharmaceutical Compounds

The USPTO granted Patent US12599608B2 to The Regents of the University of California covering methods of treating cardiac valve disease, including calcific aortic valve disease (CAVD), by administering pharmaceutical compounds of Formulae I-X. The patent names Christina Theodoris and Deepak Srivastava as inventors and includes 4 claims covering therapeutic applications and compound identification methods.

MEDICON Anti-inflammatory, Anti-cancer, and Anti-angiogenic Compounds Patent

The USPTO granted patent US12599599B2 to MEDICON PHARMACEUTICALS, INC. covering compounds of general Formula A-D-Y with anti-inflammatory, anti-cancer, and anti-angiogenic activity for treating inflammation, cancer, neurodegenerative diseases, and cardiovascular diseases. The patent includes pharmaceutical compositions, methods of making, and methods of use with 4 claims.

2-AG Enhancing Compositions for Migraine Relief

The USPTO granted Patent US12599600B2 to Arizona Board of Regents on Behalf of the University of Arizona for compositions and methods enhancing 2-arachydonyl glycerol (2AG) activity to prevent and treat headaches, particularly migraines. The patent covers methods for reducing prostaglandin activity and includes claims for pharmaceutical compositions containing 2AG-enhancing compounds.

Methods of Treating Fuchs Endothelial Corneal Dystrophy After Descemetorhexis

USPTO granted patent US12599609B2 to Kowa Company, Ltd. for methods of treating Fuchs endothelial corneal dystrophy (FECD) following descemetorhexis. The patent covers medications promoting healing in FECD patients and contains 26 claims. The inventors are Gary Gordon and Kazuhito Suehira.

PDE1 Inhibitors Treat Colon Cancer, USPTO Grant

The USPTO granted Patent US12599603B2 to Intra-Cellular Therapies, Inc. covering phosphodiesterase 1 (PDE1) inhibitors for the treatment of colon cancer and certain tumors. The patent, with inventors Peng Li and Robert Davis, claims 12 method-of-treatment claims. The application was filed on September 3, 2020.

Vemurafenib Salts for Enteroviral Infection Treatment (US12599591B2)

USPTO granted Patent US12599591B2 to Jyväskylän yliopisto for N-(3-(5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide (vemurafenib) and pharmaceutical salts for treating enteroviral diseases. The patent contains 14 claims and is classified under CPC codes A61K 31/437 and A61P 31/16.

N-Benzhydrylacetamide Inhibitors of Jumanji Domain Histone Demethylases for Cancer Treatment

USPTO granted patent US12599597B2 to the University of Kentucky Research Foundation covering substituted N-benzhydrylacetamide inhibitors of Jumanji domain histone demethylases for treating cancer via Wnt signaling pathway inhibition. The patent includes 10 claims and covers compounds according to Formula I and II, along with methods of administering these compounds to subjects needing cancer treatment.

Succinimide Anticonvulsants Treat Expressive Language Deficit in Autism

USPTO granted patent US12599581B2 to AMS Therapeutics covering a pharmacological method for treating expressive language deficit in autistic humans using succinimide anticonvulsants (ethosuximide, methsuximide, phensuximide). The patent contains 10 claims with application number 18621580 filed on March 29, 2024.

Veterinary Formulations Comprising Rapamycin and Methods of Using the Same for Treating Animal Disease

The USPTO granted Patent US12599590B2 to TriviumVet DAC covering veterinary formulations comprising rapamycin or rapalogs for treating animal diseases including cardiac dysfunction, hypertrophic cardiomyopathy, dilated cardiomyopathy, mitral valve disease, cancer, effects of aging, inflammatory disease, and viral infection in companion animals. The patent contains 15 claims and was filed on December 18, 2020.

Crystalline Forms of Quinazolinyl-Benzonitrile Compound and Ocular Formulations

USPTO granted patent US12600702B2 to Bausch + Lomb Ireland Limited for crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile and formulations thereof. The patent covers methods for treating ocular surface pain, dry eye disease, and ocular hyperemia. The application was filed on February 13, 2020 under application number 17430819, with 16 claims granted.

Compositions and Methods for Removal of NMP Degradation Products from NMP Purification Systems

USPTO granted patent US12600697B2 to Refined Technologies, Inc. covering methods for cleaning N-methyl-2-pyrrolidone (NMP) purification and recovery systems. The patent claims compositions and methods using a cleaning solution containing a solvent with a primary amine and hydroxyl group, injected into reflux drums and reboilers, circulated through separation towers to solubilize foulants, then drained. The patent was filed May 25, 2022, and contains 15 claims under CPC classifications C07D 207/267 and C07D 201/16.

Markers, Conjugates, Compositions and Methods for Hypoxia Imaging, Mapping, and Therapy

USPTO granted patent US12600742B2 to WWIKY Biosciences Inc. on April 14, 2026. The patent covers markers, conjugates, compositions and methods for hypoxia imaging, mapping, and therapy using bio-reductively activated compounds with click chemistry. Inventors include Piyush Kumar, Hassan Elsaidi, Leonard Irving Wiebe, and Michael Weinfeld. The patent includes 5 claims.

Roche Diagnostics Imidazolium Reagent Mass Spectrometry Patent Grant

The USPTO granted Patent US12600700B2 to Roche Diagnostics Operations, Inc. covering imidazolium compounds and methods for mass spectrometric determination of analyte molecules. The patent, applied for in November 2022 under application number 17991282, was granted with 14 claims. The invention relates to compounds suitable for use in mass spectrometry and associated analytical methods.

Kinase Inhibitors Patent - VIDYA Therapeutics, Inc.

USPTO granted Patent US12600698B2 to VIDYA Therapeutics, Inc. on April 14, 2026. The patent covers Bruton tyrosine kinase (BTK) inhibitors designed to penetrate the central nervous system, including pharmaceutical compositions and methods of treatment. The patent includes 21 claims with an August 2022 filing date.

N-Acylhydrazonic Compounds Treat Amyloid Diseases, Patent Grant

USPTO granted patent US12600701B2 to Faculdades Católicas for N-acylhydrazonic compounds structurally derived from 1-methyl-1H-imidazole-2-carboxaldehyde for preventing and treating amyloid degenerative aggregopathies including Alzheimer's disease, Parkinson's disease, and type 2 diabetes, as well as non-amyloid conditions such as cataracts. The patent covers four specific compounds and pharmaceutical compositions containing them.

Thiosemicarbazates and Uses Thereof - US12600699B2

The USPTO granted Patent US12600699B2 to The Feinstein Institutes for Medical Research covering thiosemicarbazates, thiocarbamates, thiocarbazates, semithiocarbazates, peptides, aza-amino acid conjugates, and azapeptides. The patent also protects a chemoselective functionalization protocol using Mitsunobu reaction for site-specific alkylation. Methods for preparing and using these compounds in drug discovery, diagnosis, inhibition, prevention and treatment of diseases are included in the 17 granted claims.

Power Sources for Wireless Intraoral Scanners

USPTO granted patent US12599286B2 to Align Technology, Inc. covering power source configurations for wireless intraoral scanners. The patent discloses an intraoral scanner with body, probe with scanner head, wireless communication module, optical sensors, and dual power sources including long-distance wireless power transfer receiver or replaceable battery as primary, and rechargeable battery or capacitor as secondary. The patent contains 22 claims.

Assist Device, Endoscope System, Assist Method and Computer-Readable Recording Medium

USPTO granted patent US12599293B2 to Olympus Corporation on April 14, 2026. The patent covers an assist device and endoscope system that uses fluorescence imaging to estimate the placement period of medical tools within body lumens. The patent contains 13 claims and is classified under CPC subclasses A61B (diagnosis/surgery) and G16H (health informatics).

AMBU A/S Articulated Endoscope Bending Section Patent

USPTO granted AMBU A/S Patent No. US12599292B2 for an articulated bending section body for an insertion endoscope. The patent covers a design with multiple segments connected by hinge members, where abutment parts are positioned at specific distances from hinges. The patent contains 23 claims and is assigned to AMBU A/S with inventor Kaspar Matthison-Hansen.

Endoscopic Camera Arrangement and Method for Camera Alignment Error Correction

The USPTO granted patent US12599288B2 to Erbe Vision GmbH for an endoscopic camera arrangement with camera alignment error correction. The patent addresses augmented reality camera calibration for laparoscopic cameras by using markers within the field of view to determine optical rotation and mechanical misalignment without additional sensors. The patent application was filed October 21, 2022, under application number 17971114, and contains 13 claims.

Sony Olympus Optical Connector Medical Device Patent Granted

USPTO granted patent US12599290B2 to Sony Olympus Medical Solutions Inc. for an optical connector and medical device. The patent covers an optical connector with an outer frame, collimator lens, and support mechanism for maintaining lens posture using a biasing member and pressing member. The patent includes 11 claims and covers CPC classifications A61B and G02B related to medical optical devices.

Capsule Endoscope Graph Component Image Analysis Patent Grant

USPTO granted patent US12599285B2 to Given Imaging Ltd. for a capsule endoscope system that analyzes in-vivo images using connected graph components and machine learning to identify pathology indicators. The patent includes 20 claims covering image processing methods for medical diagnosis.

Self-Locking Endoscope Device Patent B2

USPTO granted patent US12599287B2 to HUNAN VATHIN MEDICAL INSTRUMENT CO., LTD. on April 14, 2026, for a self-locking endoscope device. The patent includes 14 claims and covers a connecting assembly with driven gear and toggle lever, and a fitting assembly with driving gear that engages the driven gear through the toggle lever for self-locking functionality without external force.

Endoscope with Raising Base and Biasing Element

USPTO granted Patent US12599289B2 to Olympus Medical Systems Corp. for an endoscope featuring a raising base at the distal end of an insertion portion, a wire mechanism for raising the base, and a biasing element configured to apply biasing force in the raising direction. The patent includes a switching mechanism with two states controlling the wire movement. The patent contains 19 claims.

Multivalent Peptide Conjugates for Intra-Articular Joint Inflammation Treatment

USPTO granted patent US12599663B2 to VALITOR, INC. on April 14, 2026. The patent covers multivalent peptide-polymer conjugates designed for sustained intra-articular treatment of joint inflammation, with 23 claims.

ADAMTS-7 Metalloprotease Peptide Vaccine for Anti-Atherosclerosis - Beijing Kimway

The USPTO granted patent US12599654B2 to Beijing Kimway Biotech Co. Ltd. covering immunogenic peptide fragments of metalloprotease ADAMTS-7 and their use in anti-atherosclerosis vaccines. The patent, granted April 14, 2026 with an original filing date of August 20, 2020, includes 3 claims covering short peptide sequences (SEQ ID NO: 1-4) and vaccine compositions designed to inhibit vascular restenosis and atherosclerosis in mouse models.

Serum Albumin-Binding Fibronectin Type III Domains and Therapeutic Applications

USPTO granted Patent US12599652B2 to Janssen Biotech, Inc. covering fibronectin type III (FN3) domains that specifically bind to serum albumin. The patented technology includes related polynucleotides, cells expressing FN3 domains, and FN3 domains fused to heterologous moieties. The invention is designed to extend half-life of molecules in diagnostic and therapeutic applications.

Indoline Derivatives for Disease Treatment

The USPTO granted patent US12599584B2 to Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. covering indoline derivatives and pharmaceutical compositions for treating diseases associated with oxidative stress, immune response, NO release, and pro-inflammatory cytokines. The patent names Marta Weinstock-Rosin, Abraham Nudelman, and Shani Zeeli as inventors and was filed on January 19, 2017. This grant establishes intellectual property protection for the therapeutic applications of these indoline compounds.

Biphenyl Derivative Antimicrobial Adjuvant Patent Granted

USPTO granted Patent US12599575B2 to Korea Research Institute of Bioscience and Biotechnology for an antimicrobial adjuvant containing biphenyl derivative compounds as active ingredients. The patent covers technology that enhances sensitivity of gram-negative bacteria to polymyxin antibiotics, potentially reducing required dosages and associated side effects such as nephrotoxicity. The patent includes 14 claims and was filed on January 28, 2022 under Application No. 18275475.

Cenobamate Carbamate Combination Therapy Patent for Epilepsy Treatment

USPTO granted patent US12599585B2 to SK Biopharmaceuticals covering combination therapy using cenobamate [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate with antiepileptic drugs for preventing or treating neurological disorders such as epilepsy. The patent contains 5 claims and lists inventors Marc Kamin and Laurent Vernillet.

Chlorinated Tetralin Compounds and Pharmaceutical Compositions

USPTO granted patent US12599587B2 to Springworks Therapeutics, Inc. on April 14, 2026. The patent covers chlorinated tetralin compounds and pharmaceutical compositions, classified under C07D 233/88 and A61K 31/417. The application (No. 18490993) was filed on October 20, 2023, and the granted patent contains 19 claims.

Bayer Aktiengesellschaft Substituted Isophthalic Acid Diamides Herbicide Patent, US12599136B2

The USPTO granted Patent US12599136B2 to Bayer Aktiengesellschaft covering substituted isophthalic acid diamides of general formula (I) for use as herbicides. The patent includes 15 claims covering compounds where X and Y are hydrogen, alkyl, or halogen radicals, and Z1 and Z2 are alkyl, cycloalkyl, or phenyl radicals with a heterocyclic Q ring. The patent was filed April 1, 2021, under Application No. 17995662.

Pyrrole Compounds Patent - Aligos Therapeutics - US12599582B2

USPTO granted Patent US12599582B2 to Aligos Therapeutics covering pyrrole compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions, and methods of treating diseases and conditions. The patent names inventors Sandrine Vendeville, David Bernard Smith, Leonid Beigelman, and Vladimir Serebryany. The application was filed August 22, 2023, with 2 claims granted.

Japan Science and Technology Agency V-ATPase Inhibitor Patent

USPTO granted patent US12599588B2 to Japan Science and Technology Agency for an inhibitor of Na+-translocating V-ATPase activity. The compound serves as an antibacterial agent and medicine with applications in antibacterial and screening methods. The patent application was filed January 15, 2020, contains 12 claims, and covers compounds with specific structural features including hydroxy, alkoxy, and amino substituents on phenyl groups.

Center for Tobacco Products Complaint, Apr 13, 2026

FDA Center for Tobacco Products (CTP) filed a complaint on April 13, 2026. The document is classified as closed in the Regulations.gov system (Docket FDA-2026-H-3804). The full complaint text is not available for public viewing on the regulatory portal. This appears to be a formal complaint related to tobacco product regulation.

BILTRICIDE Not Withdrawn for Safety or Effectiveness

FDA has determined under 21 CFR 314.161 that BILTRICIDE (praziquantel) oral tablet, 600 mg, was not withdrawn from sale for reasons of safety or effectiveness. The drug product, which was discontinued by Bayer Healthcare Pharmaceuticals in February 2024 and moved to the Orange Book's Discontinued Drug Product List, retains its eligibility for ANDA approvals. Novitium Pharma LLC submitted a citizen petition requesting this determination, which FDA granted based on review of Agency records.

FDA DMB Acknowledgment Letter to Hyman Phelps McNamara

FDA Division of Manufacturing and Quality (DMB) within CDER sent an acknowledgment letter to Hyman, Phelps & McNamara, P.C. in response to submission FDA-2026-P-4018. The acknowledgment indicates receipt of the submission without substantive review or determination at this stage. No regulatory obligations, compliance deadlines, or enforcement actions are imposed by this document.

Suitability Petition to FDA

Hyman, Phelps & McNamara, P.C. filed a Suitability Petition with the FDA under docket FDA-2026-P-4020-0001. The petition appears to request FDA approval for a drug product change under applicable administrative procedures. The filing was submitted to CDER for review.

FDA Suitability Petition, Comment Period Open

FDA Suitability Petition, Comment Period Open

Robeson County Behavioral Health Urgent Care Ribbon-Cutting Ceremony

North Carolina DHHS announces a ribbon-cutting ceremony for a new Behavioral Health Urgent Care facility in Robeson County on April 17, 2026. NCDHHS provided $2.2 million in funding as part of a historic mental health investment from the North Carolina General Assembly. This is the eighth of a planned 13 new or expanded BHUCs to open statewide.

MDHHS Encourages Syphilis Testing During STI Awareness Week; Cases Up 50%

MDHHS is urging Michigan residents to get tested for syphilis during STI Awareness Week (April 12-18) following a 50% increase in symptomatic and infectious syphilis cases over the past decade. Preliminary 2025 data show rising rates across all populations, including a record 58 congenital syphilis cases in 2024 — the highest in Michigan in over 30 years. The department recommends regular testing, early prenatal care with syphilis screening in the first and third trimesters, and consideration of doxycycline post-exposure prophylaxis (doxy PEP) for exposed individuals.